The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults

References

• Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23:Suppl S274 - 9; PMID: 15597069
   PubMedGoogle Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:Suppl 2 B51 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.04.063; PMID: 19477562
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184 - 91; http://dx.doi.org/10.1086/649209; PMID: 20001736
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36:679 - 83; http://dx.doi.org/10.1086/367858; PMID: 12627350
   PubMed Web of Science ®Google Scholar
• Saudi Ministry of Health Requirements—Hajj. Cited 2012 Jan 9. Available from: http://www.hajinformation.com/main/p3001.htm
   Google Scholar
• Kenah E, Chao DL, Matrajt L, Halloran ME, Longini IM Jr. The global transmission and control of influenza. PLoS One 2011; 6:e19515; http://dx.doi.org/10.1371/journal.pone.0019515; PMID: 21573121
   PubMedGoogle Scholar
• Østergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161 - 8; http://dx.doi.org/10.1016/j.vaccine.2008.08.075; PMID: 18834910
   PubMed Web of Science ®Google Scholar
• Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744 - 53; http://dx.doi.org/10.1016/j.vaccine.2009.10.064; PMID: 19887137
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41 - 8; http://dx.doi.org/10.1097/INF.0b013e3182054ab9; PMID: 21200360
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274 - 84; http://dx.doi.org/10.1016/j.vaccine.2011.03.043; PMID: 21443965
   PubMed Web of Science ®Google Scholar
• Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56 - 62; http://dx.doi.org/10.1097/INF.0b013e31820e6e02; PMID: 21278617
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264 - 73; http://dx.doi.org/10.1016/j.vaccine.2011.03.009; PMID: 21420417
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang L-M, Dubey AP, Jain H, Bavdekar A, Lin T-Y, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239 - 47; http://dx.doi.org/10.4161/hv.7.2.14068; PMID: 21343698
   PubMed Web of Science ®Google Scholar
• Nauta JJP, de Bruijn IA. The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals. Vaccine 2006; 24:6643 - 4; http://dx.doi.org/10.1016/j.vaccine.2006.05.053; PMID: 16797109
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780 - 6; PMID: 12965904
   PubMedGoogle Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine 2005; 23:2222 - 7; http://dx.doi.org/10.1016/j.vaccine.2005.01.051; PMID: 15755600
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840 - 7; http://dx.doi.org/10.1128/CVI.00529-09; PMID: 20219881
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001; 69:1568 - 73; http://dx.doi.org/10.1128/IAI.69.3.1568-1573.2001; PMID: 11179328
   PubMed Web of Science ®Google Scholar
• Weston WM, Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine 2011; 29:1017 - 22; http://dx.doi.org/10.1016/j.vaccine.2010.11.057; PMID: 21134450
   PubMed Web of Science ®Google Scholar
• Chioato A, Noseda E, Felix SD, Stevens M, Del Giudice G, Fitoussi S, et al. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clin Vaccine Immunol 2010; 17:1952 - 7; http://dx.doi.org/10.1128/CVI.00175-10; PMID: 20962212
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al, The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156 - 67; PMID: 9067649
   PubMedGoogle Scholar
• Gill CJ, Ram S, Welsch JA, Detora L, Anemona A. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine 2011; 30:29 - 34; http://dx.doi.org/10.1016/j.vaccine.2011.10.068; PMID: 22075087
   PubMed Web of Science ®Google Scholar